Pharmacology of Mupirocin in Nasal Application in Healthy Volunteers: Monocentric Study

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

February 29, 2024

Primary Completion Date

March 4, 2025

Study Completion Date

December 31, 2025

Conditions
HealthyStaphylococcus Aureus Infection
Interventions
DRUG

Mupirocin (50 mg)

50 mg de mupirocin

DRUG

Mupirocin (500 mg)

500 mg de mupirocin

BIOLOGICAL

blood samples after Single dose part

3 blood samples will be performed sampling time ater application of mupirocin (single dose part): 00h30, 1h00, 02h00

DIAGNOSTIC_TEST

nasal swab after Single dose part

7 nasal swab for the detection of S. aureus (type Swab) will be performed after application of mupirocin (single dose part): 00h00, 1h00, 02h00, 04h00, 06h00, 08h00, 12h00

OTHER

Collection of urine after Single dose part

Collection of urine during 12 hours after the application of mupirocin (Single dose part)

DIAGNOSTIC_TEST

nasal swab during Repeated dose part

5 nasal swab for the detection of S. aureus (type Swab) will be performed during administration of mupirocin (Repeated dose part): 2, 3, 4, 5 et 6 days after the first application of mupirocin (Repeated dose part)

OTHER

Collection of urine during Repeated dose part

5 collections of urine during Repeated dose part: 2, 3, 4, 5 et 6 days after the first application of mupirocin (Repeated dose part)

OTHER

nasal swab after Repeated dose part

2 nasal swab for the detection of S. aureus (type Swab) will be performed: 1, 3 months after the first application of mupirocin (Repeated dose part)

Trial Locations (1)

Unknown

CHU de SAINT-ETIENNE, Saint-Etienne

All Listed Sponsors
lead

Centre Hospitalier Universitaire de Saint Etienne

OTHER